116 related articles for article (PubMed ID: 25765978)
1. [Development of new therapies targeting human papillomavirus molecules].
Kawana K
Uirusu; 2014; 64(1):35-42. PubMed ID: 25765978
[TBL] [Abstract][Full Text] [Related]
2. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients.
Kawana K; Adachi K; Kojima S; Taguchi A; Tomio K; Yamashita A; Nishida H; Nagasaka K; Arimoto T; Yokoyama T; Wada-Hiraike O; Oda K; Sewaki T; Osuga Y; Fujii T
Vaccine; 2014 Oct; 32(47):6233-9. PubMed ID: 25258102
[TBL] [Abstract][Full Text] [Related]
3. Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes.
Nishida H; Matsumoto Y; Kawana K; Christie RJ; Naito M; Kim BS; Toh K; Min HS; Yi Y; Matsumoto Y; Kim HJ; Miyata K; Taguchi A; Tomio K; Yamashita A; Inoue T; Nakamura H; Fujimoto A; Sato M; Yoshida M; Adachi K; Arimoto T; Wada-Hiraike O; Oda K; Nagamatsu T; Nishiyama N; Kataoka K; Osuga Y; Fujii T
J Control Release; 2016 Jun; 231():29-37. PubMed ID: 26979870
[TBL] [Abstract][Full Text] [Related]
4. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells.
Komatsu A; Igimi S; Kawana K
Vaccine; 2018 Jun; 36(24):3423-3426. PubMed ID: 29735324
[TBL] [Abstract][Full Text] [Related]
5. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7.
Adachi K; Kawana K; Yokoyama T; Fujii T; Tomio A; Miura S; Tomio K; Kojima S; Oda K; Sewaki T; Yasugi T; Kozuma S; Taketani Y
Vaccine; 2010 Apr; 28(16):2810-7. PubMed ID: 20170766
[TBL] [Abstract][Full Text] [Related]
6. Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo.
Jung HS; Rajasekaran N; Song SY; Kim YD; Hong S; Choi HJ; Kim YS; Choi JS; Choi YL; Shin YK
Int J Mol Sci; 2015 May; 16(6):12243-60. PubMed ID: 26035754
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner.
Taguchi A; Kawana K; Yokoyama T; Adachi K; Yamashita A; Tomio K; Kojima S; Oda K; Fujii T; Kozuma S
Vaccine; 2012 Aug; 30(36):5368-72. PubMed ID: 22727726
[TBL] [Abstract][Full Text] [Related]
8. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo.
Zhou J; Peng C; Li B; Wang F; Zhou C; Hong D; Ye F; Cheng X; Lü W; Xie X
Gynecol Oncol; 2012 Feb; 124(2):296-302. PubMed ID: 22056554
[TBL] [Abstract][Full Text] [Related]
10. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.
Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK
Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes.
Zhou J; Li B; Peng C; Wang F; Fu Z; Zhou C; Hong D; Ye F; Lü W; Xie X
Antiviral Res; 2013 May; 98(2):305-13. PubMed ID: 23523766
[TBL] [Abstract][Full Text] [Related]
12. Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer.
Fujii T; Saito M; Iwasaki E; Ochiya T; Takei Y; Hayashi S; Ono A; Hirao N; Nakamura M; Kubushiro K; Tsukazaki K; Aoki D
Int J Oncol; 2006 Sep; 29(3):541-8. PubMed ID: 16865269
[TBL] [Abstract][Full Text] [Related]
13. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma.
Liu WL; Green N; Seymour LW; Stevenson M
Cancer Gene Ther; 2009 Oct; 16(10):764-75. PubMed ID: 19363466
[TBL] [Abstract][Full Text] [Related]
16. Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA.
Yamato K; Fen J; Kobuchi H; Nasu Y; Yamada T; Nishihara T; Ikeda Y; Kizaki M; Yoshinouchi M
Cancer Gene Ther; 2006 Mar; 13(3):234-41. PubMed ID: 16138119
[TBL] [Abstract][Full Text] [Related]
17. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
Chan PK; Liu SJ; Cheung JL; Cheung TH; Yeo W; Chong P; Man S
J Med Virol; 2011 Jun; 83(6):1023-30. PubMed ID: 21503915
[TBL] [Abstract][Full Text] [Related]
18. Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers.
Chang JT; Kuo TF; Chen YJ; Chiu CC; Lu YC; Li HF; Shen CR; Cheng AJ
Cancer Gene Ther; 2010 Dec; 17(12):827-36. PubMed ID: 20885450
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
20. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
